ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2015
Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease.
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization.Alzheimer's research & therapy · 2021Article
- Data-driven multiple-level analysis of gut-microbiome-immune-joint interactions in rheumatoid arthritis.BMC genomics · 2019Article
- Context-sensitive network analysis identifies food metabolites associated with Alzheimer's disease: an exploratory study.BMC medical genomics · 2019Article
- Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.Oncogene · 2018Article
- Disease comorbidity-guided drug repositioning: a case study in schizophrenia.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2018Article
- Context-sensitive network-based disease genetics prediction and its implications in drug discovery.Bioinformatics (Oxford, England) · 2017Article
- Combining mechanism-based prediction with patient-based profiling for psoriasis metabolomics biomarker discovery.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2017Article
- Interrogating Patient-level Genomics and Mouse Phenomics towards Understanding Cytokines in Colorectal Cancer Metastasis.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2017Article
- Drug repurposing for glioblastoma based on molecular subtypes.Journal of biomedical informatics · 2016Article
- Phenome-based gene discovery provides information about Parkinson's disease drug targets.BMC genomics · 2016Article
- Towards understanding brain-gut-microbiome connections in Alzheimer's disease.BMC systems biology · 2016Article
- A genomics-based systems approach towards drug repositioning for rheumatoid arthritis.BMC genomics · 2016Article
- Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a severe neurodegenerative disorder without effective treatments. Here, we present a novel drug repositioning approach to predict new drugs for PD leveraging both disease genetics and large amounts of mouse model phenotypes. First, we identified PD-specific mouse phenotypes using well-studied human disease genes. Then we searched all FDA-approved drugs for candidates that share similar mouse phenotype profiles with PD. We demonstrated the validity of our approach using drugs that have been approved for PD: 10 approved PD drugs were ranked within top 10% among 1197 candidates. In predicting novel PD drugs, our approach achieved a mean average precision of 0.24, which is significantly higher (p<e-11) than 0.16 for a state-of-art drug discovery approach based on mouse phenotype data. Comparison of gene expression profiles between PD and top-ranked drug candidates indicates that quetiapine has the potential to treat PD.
Indexed as
Identifiers
26958284PMC4765695W2342000326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.